Clinical Trials

Fast Facts

Our clinical trials portfolio includes:

  • More than 40 research studies
  • More than 10 Pediatric-focused studies
  • Five phase-1 Trials
  • First-In-Human treatments
  • Investigational New Drugs developed at UF

Featured Trial

PNOC 020

A Phase I/II Study of RNA-lipid particle (RNA-LP) vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM).

Subject inclusion criteria:

  • Age: 21 Years and older (Adult, Older Adult)
  • Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma) (secondary GBM not eligible) that is MGMT unmethylated.
  • The tumor must have a supratentorial component.
  • Bone Marrow, Renal and Hepatic tests

See full inclusion criteria and learn more about the PNOC 020 Clinical Trial

Contact Marcia Hodik to hear more about the PNOC 020 Clinical Trial.

 


Browse or search current neurosurgery clinical trials

PNOC 013

A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma

Adult or Pediatric?

Both

Type of Study
  • Randomized
  • Drug
  • Treatment
  • Interventional
Disease

Central Nervous System Tumor

Disease Type

DIPG
Newly diagnosed high-grade glioma
Recurrent high-grade glioma